Nanotechnology in Drug Delivery Market Report 2022-2032: Forecasts by Technology, by Application, by Nanoparticles, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery Scenarios

Description

List of Tables

Title:
Nanotechnology in Drug Delivery Market Report 2022-2032
Forecasts by Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles, Nanotubes), by Application (Neurology, Oncology, Cardiovascular/ Physiology, Anti-inflammatory/Immunology, Anti-infective, Other), by Nanoparticles (Dendrimers, Gold Nanoparticles, Fullerenes, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

The Nanotechnology in Drug Delivery Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Nanoparticles are Gaining Tractions in the Global Market for Drug Deliveries

Nanomedicine is a relatively recent field in which nanotechnology knowledge & technology are used for disease prevention and treatment. It comprises the diagnostic, transport, and sensing functions of nanostructured materials including nano robots, nano sensors, and also the activation of nanomaterials in living cells. For example, a nanomaterials cancer diagnostic approach has been developed that incorporates both medicine and imaging modalities. Lipid systems such like lipid nanoparticles and micelles, which are both now FDA-approved, were used in the first generation of nanoparticle-based treatment. These liposomes and micelles include inorganic nanomaterials such like gold or magnetic nanoparticles. Due to these characteristics, inorganic nanoparticles are increasingly being used for delivery of drug, imaging, and therapeutic applications.

What Questions Should You Ask before Buying a Market Research Report?

How is the nanotechnology in drug delivery market evolving?

What is driving and restraining the nanotechnology in drug delivery market?

How will each nanotechnology in drug delivery submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?

How will the market shares for each nanotechnology in drug delivery submarket develop from 2022 to 2032?

What will be the main drivers for the overall market from 2022 to 2032?

Will leading nanotechnology in drug delivery markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?

Who are the leading players and what are their prospects over the forecast period?

What are the nanotechnology in drug delivery projects for these leading companies?

How will the industry evolve during the period between 2020 and 2032? What are the implication of nanotechnology in drug delivery projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the nanotechnology in drug delivery market?

Where is the nanotechnology in drug delivery market heading? And how can you ensure you are at the forefront of the market?

What can be the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the nanotechnology in drug delivery market today, and over the next 10 years:

Our 470+ page report provides 320 tables and 304 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

Contains in-depth analyse of global, regional and national sales and growth

Highlights for you the key successful trends, changes and revenue projections made by your competitors

This report tells you TODAY how the nanotechnology in drug delivery market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal the commercial prospects

In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.

You find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising nanotechnology in drug delivery prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V" , "L" , "W" and "U" are discussed in this report.

Segments Covered in this report:

Technology

Nanocrystals
Nanoparticles
Liposomes
Micelles
Nanotubes

Application

Neurology
Oncology
Cardiovascular/ Physiology
Anti-inflammatory/ Immunology
Anti-infective
Other Application

Nanoparticles

Dendrimers
Gold Nanoparticles
Fullerenes
Other Nanoparticles

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:

North America

U.S.
Canada
Mexico

Europe

Germany
Spain
United Kingdom
France
Italy
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of Asia Pacific

LAMEA

Brazil
Turkey
Saudi Arabia
South Africa
UAE
Rest of Latin America, Middle East and Africa

The report also includes profiles and for some of the leading companies in the Nanotechnology in Drug Delivery Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

AbbVie Inc. (AbbVie)
Amgen Inc.
Aquanova AG
Bayer AG
Camarus AB
Celgene Corporation
Cytimmune Sciences
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co., Inc.
Nanobiotix
NanoCarrier Co, Ltd
NanOlogy LLC
Novartis AG
Pfizer Inc. (Pfizer)
Roche Holding AG (Roche)
Sanofi SA
Selecta Biosciences Inc.
Starpharma Holdings Limited
Taiwan Liposome Co.
Tarveda Therapeutics

Overall world revenue for Nanotechnology in Drug Delivery Market, 2022 to 2032 in terms of value the market will surpass US$59.5 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Nanotechnology in Drug Delivery Market, 2022 to 2032 Market report helps you?

In summary, our 472-page report provides you with the following knowledge:

Revenue forecasts to 2032 for Nanotechnology in Drug Delivery Market, 2022 to 2032 Market, with forecasts for technology, application, nanoparticles each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues

Revenue forecasts to 2032 for 4 regional and 20 key national markets - See forecasts for the Nanotechnology in Drug Delivery Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market- including company profiles for 21 of the major companies involved in the Nanotechnology in Drug Delivery Market, 2022 to 2032 Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Nanotechnology in Drug Delivery Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.

Visiongain is a trading partner with the US Federal Government.

Product Code: PHA1175

1. Report Overview

1.1. Introduction to Nanotechnology in Drug Delivery Market
1.2. Global Nanotechnology in Drug Delivery Market Overview
1.3. What Are the Objectives of this Report?
1.4. What is the Scope of the Report?
1.5. Nanotechnology in Drug Delivery Market Definition
1.6. Why You Should Read this Report
1.7. What this Report Delivers
1.8. Key Questions Answered by this Analytical Report Include:
1.9. Who is this Report for?
1.10. Research Methodology
- 1.10.1. Primary Research
- 1.10.2. Secondary Research
- 1.10.3. Market Evaluation & Forecasting Methodology
1.11. Frequently Asked Questions (FAQs)
1.12. Associated Visiongain Reports
1.13. About Visiongain

2. Executive Summary

3. Global Market Dynamics

3.1. Market Driving Factors
- 3.1.1. Increased Use of Inorganic Nanoparticles with a Focus on Medication Delivery
- 3.1.2. Drug Delivery Using Nanotechnology
- 3.1.3. Increasing Development of Nanotechnology and Nanomaterials
- 3.1.4. Advancements in Nanoscale Technologies
- 3.1.5. Growing Preference for Personalized Medicines
3.2. Market Restraining Factors
- 3.2.1. Large-Scale Production is a Problem in Nanomaterials R&D for Medication Delivery
- 3.2.2. New Regulatory Control Challenges
- 3.2.3. Safety Issues for Nanotechnology
- 3.2.4. Certain Restrictions of Using Nanoparticles with X-Ray
3.3. Opportunities in the Global Market
- 3.3.1. Nanotechnology is Important in the Development of Drug Delivery Technologies
- 3.3.2. Nanoscale Has a Number of Advantages
- 3.3.3. Nanotechnology is Undergoing in a Great Deal of Research and Development
3.4. Challenges in the Global Market
- 3.4.1. Complication of Nanotechnology Delivery Services
- 3.4.2. Formulation Scientists Face a Hurdle When it Comes to Drug Distribution to Ocular Tissues
- 3.4.3. Low Bioavailability is a Problem with Most Medication Delivery Technologies
3.5. SWOT Analysis
3.6. PEST Analysis
3.7. Porter's Five Forces Analysis
- 3.7.1. Competitive Rivalry
- 3.7.2. Bargaining Power of Suppliers
- 3.7.3. Bargaining Power of Customers
- 3.7.4. Threat of New Entrants
- 3.7.5. Threat of Substitutes

4. Global Nanotechnology in Drug Delivery Market Analysis

4.1. Global Market Outlook
4.2. Global Market Size Estimation and Forecast
- 4.2.1. Pre-COVID-19 Market Scenario
- 4.2.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

5. Global Nanotechnology in Drug Delivery Market Analysis by Region

5.1. North America
5.2. Europe
5.3. Asia-Pacific
5.4. LAMEA
5.5. Regional Market Size Estimation and Forecast
- 5.5.1. Pre-COVID-19 Market Scenario
- 5.5.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

6. Global Market Size Estimation and Forecast by Technology

6.1. Nanocrystals
6.2. Nanoparticles
6.3. Liposomes
6.4. Micelles
6.5. Nanotubes
6.6. Pre-COVID-19 Market Scenario
6.7. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

7. Global Market Size Estimation and Forecast by Application

7.1. Neurology
7.2. Oncology
7.3. Cardiovascular/ Physiology
7.4. Anti-inflammatory/ Immunology
7.5. Others
- 7.5.1. Nanotechnology Application in Hematology
- 7.5.2. Nanotechnology Application in Ophthalmology
7.6. Pre-COVID-19 Market Scenario
7.7. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

8. Global Market Size Estimation and Forecast by Nanoparticle

8.1. Dendrimers
8.2. Gold Nanoparticles
8.3. Fullerenes
8.4. Other Nanoparticles
8.5. Pre-COVID-19 Market Scenario
8.6. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

9. North America Market Size Estimation and Forecast

9.1. Market Outlook
9.2. North America Market Size Estimation and Forecast
- 9.2.1. Pre-COVID-19 Market Scenario
- 9.2.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.3. Country Market Size Estimation and Forecast
- 9.3.1. Pre-COVID-19 Market Scenario
- 9.3.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.4. North America Market Size Estimation and Forecast Technology
- 9.4.1. Pre-COVID-19 Market Scenario
- 9.4.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.5. North America Market Size Estimation and Forecast Application
- 9.5.1. Pre-COVID-19 Market Scenario
- 9.5.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.6. North America Market Size Estimation and Forecast Nanoparticle
- 9.6.1. Pre-COVID-19 Market Scenario
- 9.6.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.7. U.S. Nanotechnology in Drug Delivery Market Analysis
- 9.7.1. Nanotechnology Advances in the United States
- 9.7.2. Pre-COVID-19 Market Scenario
- 9.7.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.8. Canada Nanotechnology in Drug Delivery Market Analysis
- 9.8.1. Increasing Demand of Nanotechnology in Canada
- 9.8.2. Pre-COVID-19 Market Scenario
- 9.8.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9.9. Mexico Nanotechnology in Drug Delivery Market Analysis
- 9.9.1. Development of Nanoscience and Nanotechnologies (NCT) in Mexico
- 9.9.2. Pre-COVID-19 Market Scenario
- 9.9.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

10. Europe Market Size Estimation and Forecast

10.1. Market Outlook
10.2. Europe Market Size Estimation and Forecast
- 10.2.1. Pre-COVID-19 Market Scenario
- 10.2.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.3. Country Market Size Estimation and Forecast
- 10.3.1. Pre-COVID-19 Market Scenario
- 10.3.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.4. Europe Market Size Estimation and Forecast Technology
- 10.4.1. Pre-COVID-19 Market Scenario
- 10.4.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.5. Europe Market Size Estimation and Forecast Application
- 10.5.1. Pre-COVID-19 Market Scenario
- 10.5.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.6. Europe Market Size Estimation and Forecast Nanoparticle
- 10.6.1. Pre-COVID-19 Market Scenario
- 10.6.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.7. Germany Nanotechnology in Drug Delivery Market Analysis
- 10.7.1. Nanotechnology is One of the Most Innovative Technology Industries in Germany
- 10.7.2. Pre-COVID-19 Market Scenario
- 10.7.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.8. UK Nanotechnology in Drug Delivery Market Analysis
- 10.8.1. In UK There is Significant Investments in Nanotechnology
- 10.8.2. Pre-COVID-19 Market Scenario
- 10.8.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.9. France Nanotechnology in Drug Delivery Market Analysis
- 10.9.1. In Order to Improve Drug Safety, a Nanomedicine Company Has been Established in France.
- 10.9.2. Pre-COVID-19 Market Scenario
- 10.9.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.10. Italy Nanotechnology in Drug Delivery Market Analysis
- 10.10.1. Nanotechnology Drug Research and Development Companies in Italy
- 10.10.2. Pre-COVID-19 Market Scenario
- 10.10.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.11. Spain Nanotechnology in Drug Delivery Market Analysis
- 10.11.1. Nanomedicine and Drug Delivery Technologies Are Crucial in Modern Medicine in Spain
- 10.11.2. Pre-COVID-19 Market Scenario
- 10.11.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10.12. Rest of Europe Nanotechnology in Drug Delivery Market Analysis
- 10.12.1. Pre-COVID-19 Market Scenario
- 10.12.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

11. Asia-Pacific Market Size Estimation and Forecast

11.1. Market Outlook
11.2. Asia-Pacific Market Size Estimation and Forecast
- 11.2.1. Pre-COVID-19 Market Scenario
- 11.2.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.3. Country Market Size Estimation and Forecast
- 11.3.1. Pre-COVID-19 Market Scenario
- 11.3.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.4. Asia-Pacific Market Size Estimation and Forecast Technology
- 11.4.1. Pre-COVID-19 Market Scenario
- 11.4.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.5. Asia-Pacific Market Size Estimation and Forecast Application
- 11.5.1. Pre-COVID-19 Market Scenario
- 11.5.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.6. Asia-Pacific Market Size Estimation and Forecast Nanoparticle
- 11.6.1. Pre-COVID-19 Market Scenario
- 11.6.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.7. China Nanotechnology in Drug Delivery Market Analysis
- 11.7.1. China's Nanotechnology Sector Continues to Expand at a Rapid Pace
- 11.7.2. Pre-COVID-19 Market Scenario
- 11.7.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.8. India Nanotechnology in Drug Delivery Market Analysis
- 11.8.1. In India, Biopharmaceutical Companies Enabled Nanotechnology Drug Delivery
- 11.8.2. Pre-COVID-19 Market Scenario
- 11.8.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.9. Japan Nanotechnology in Drug Delivery Market Analysis
- 11.9.1. Drug Delivery Systems (DDS) for Drugs Such as Anti-Cancer Therapeutics and Nucleic Acids Were Developed in Japan.
- 11.9.2. Pre-COVID-19 Market Scenario
- 11.9.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.10. South Korea Nanotechnology in Drug Delivery Market Analysis
- 11.10.1. South Korean Pharmaceutical Companies Are Hesitant to Invest More in Drug Discovery and Delivery Systems Based on Natural Products
- 11.10.2. Pre-COVID-19 Market Scenario
- 11.10.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.11. Australia Nanotechnology in Drug Delivery Market Analysis
- 11.11.1. Australia is a Leader in Nanotechnology Research and Development
- 11.11.2. Pre-COVID-19 Market Scenario
- 11.11.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11.12. Rest of Asia-Pacific Nanotechnology in Drug Delivery Market Analysis
- 11.12.1. Pre-COVID-19 Market Scenario
- 11.12.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

12. LAMEA Market Size Estimation and Forecast

12.1. Market Outlook
12.2. LAMEA Market Size Estimation and Forecast
- 12.2.1. Pre-COVID-19 Market Scenario
- 12.2.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.3. Country Market Size Estimation and Forecast
- 12.3.1. Pre-COVID-19 Market Scenario
- 12.3.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.4. LAMEA Market Size Estimation and Forecast Technology
- 12.4.1. Pre-COVID-19 Market Scenario
- 12.4.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.5. LAMEA Market Size Estimation and Forecast Application
- 12.5.1. Pre-COVID-19 Market Scenario
- 12.5.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.6. LAMEA Market Size Estimation and Forecast Nanoparticle
- 12.6.1. Pre-COVID-19 Market Scenario
- 12.6.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.7. Brazil Nanotechnology in Drug Delivery Market Analysis
- 12.7.1. Nanotechnology Sector is Innovating and Developing Applications in Biotech, Medicine, and Pharmaceuticals
- 12.7.2. Pre-COVID-19 Market Scenario
- 12.7.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.8. South Africa Nanotechnology in Drug Delivery Market Analysis
- 12.8.1. South Africa is Experimenting with Nanotechnology to Improve Tuberculosis Treatments
- 12.8.2. Pre-COVID-19 Market Scenario
- 12.8.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.9. South Arabia Nanotechnology in Drug Delivery Market Analysis
- 12.9.1. Nanotechnology is Essential in Medical and Pharmaceutical Delivery in Saudi Arabia
- 12.9.2. Pre-COVID-19 Market Scenario
- 12.9.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.10. Turkey Nanotechnology in Drug Delivery Market Analysis
- 12.10.1. Nanomaterials and Nano-Drug Delivery Systems in Human and Veterinary Medicine Are Emerging Technologies in Turkey
- 12.10.2. Pre-COVID-19 Market Scenario
- 12.10.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.11. UAE Nanotechnology in Drug Delivery Market Analysis
- 12.11.1. Research & Development of Nanotechnology in UAE
- 12.11.2. Pre-COVID-19 Market Scenario
- 12.11.3. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.12. Rest of LAMEA Nanotechnology in Drug Delivery Market Analysis
- 12.12.1. Pre-COVID-19 Market Scenario
- 12.12.2. Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)

13. Company Profiles

13.1. Merck & Co., Inc.
- 13.1.1. Company Snapshot
- 13.1.2. Company Overview
- 13.1.3. Company Financial Profile
- 13.1.4. Company Product Benchmarking
- 13.1.5. Company Recent Developments
13.2. Bayer AG
- 13.2.1. Company Snapshot
- 13.2.2. Company Overview
- 13.2.3. Company Financial Profile
- 13.2.4. Company Product Benchmarking
- 13.2.5. Company Recent Developments
13.3. Amgen, Inc
- 13.3.1. Company Snapshot
- 13.3.2. Company Overview
- 13.3.3. Company Financial Profile
- 13.3.4. Company Product Benchmarking
- 13.3.5. Company Recent Developments
13.4. Pfizer Inc.
- 13.4.1. Company Snapshot
- 13.4.2. Company Overview
- 13.4.3. Company Financial Profile
- 13.4.4. Company Product Benchmarking
- 13.4.5. Company Recent Developments
13.5. Novartis AG
- 13.5.1. Company Snapshot
- 13.5.2. Company Overview
- 13.5.3. Company Financial Profile
- 13.5.4. Company Product Benchmarking
- 13.5.5. Company Recent Developments
13.6. AbbVie Inc.
- 13.6.1. Company Snapshot
- 13.6.2. Company Overview
- 13.6.3. Company Financial Profile
- 13.6.4. Company Product Benchmarking
- 13.6.5. Company Recent Developments
13.7. Roche Holding AG
- 13.7.1. Company Snapshot
- 13.7.2. Company Overview
- 13.7.3. Company Financial Profile
- 13.7.4. Company Product Benchmarking
- 13.7.5. Company Recent Developments
13.8. Johnson & Johnson
- 13.8.1. Company Snapshot
- 13.8.2. Company Overview
- 13.8.3. Company Financial Profile
- 13.8.4. Company Product Benchmarking
- 13.8.5. Company Recent Developments
13.9. Glaxo SmithKline plc.
- 13.9.1. Company Snapshot
- 13.9.2. Company Overview
- 13.9.3. Company Financial Profile
- 13.9.4. Company Product Benchmarking
- 13.9.5. Company Recent Developments
13.10. Sanofi SA
- 13.10.1. Company Snapshot
- 13.10.2. Company Overview
- 13.10.3. Company Financial Profile
- 13.10.4. Company Product Benchmarking
- 13.10.5. Company Recent Developments
13.11. Celgene Inc (A Bristol-Myers Squibb Company)
- 13.11.1. Company Snapshot
- 13.11.2. Company Overview
- 13.11.3. Product Benchmarking
- 13.11.4. Strategic Outlook
13.12. Aquanova AG
- 13.12.1. Company Snapshot
- 13.12.2. Company Overview
- 13.12.3. Product Benchmarking
13.13. Cytimmune Sciences, Inc.
- 13.13.1. Company Snapshot
- 13.13.2. Company Overview
- 13.13.3. Product Benchmarking
- 13.13.4. Strategic Outlook
13.14. Nanobiotix
- 13.14.1. Company Snapshot
- 13.14.2. Company Overview
- 13.14.3. Product Benchmarking
- 13.14.4. Strategic Outlook
13.15. NanoCarrier Co, Ltd
- 13.15.1. Company Snapshot
- 13.15.2. Company Overview
- 13.15.3. Product Benchmarking
- 13.15.4. Strategic Outlook
13.16. NanOlogy LLC
- 13.16.1. Company Snapshot
- 13.16.2. Company Overview
- 13.16.3. Product Benchmarking
- 13.16.4. Strategic Outlook
13.17. Taiwan Liposome Co.
- 13.17.1. Company Snapshot
- 13.17.2. Company Overview
- 13.17.3. Product Benchmarking
- 13.17.4. Strategic Outlook
13.18. Tarveda Therapeutics
- 13.18.1. Company Snapshot
- 13.18.2. Company Overview
- 13.18.3. Product Benchmarking
- 13.18.4. Strategic Outlook
13.19. Camarus AB
- 13.19.1. Company Snapshot
- 13.19.2. Company Overview
- 13.19.3. Product Benchmarking
- 13.19.4. Strategic Outlook
13.20. Selecta Biosciences
- 13.20.1. Company Snapshot
- 13.20.2. Company Overview
- 13.20.3. Financial Analysis
- 13.20.4. Product Benchmarking
- 13.20.5. Strategic Outlook
13.21. Starpharma Holdings Limited
- 13.21.1. Company Snapshot
- 13.21.2. Company Overview
- 13.21.3. Financial Analysis
- 13.21.4. Product Benchmarking
- 13.21.5. Strategic Outlook

14. Conclusion and Recommendations

14.1. Concluding Remarks
14.2. Recommendations for Market Players